14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IMDX vs MYGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas MYGN carries 45.4/100 (HOLD) at $5.54 (54.0x Forward P/E, -13.3% operating margin).
Growth vs. Quality Trade-Off: MYGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. IMDX 45.5/100 HOLD) and 0.63β · 54% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile MYGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $530.4M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment81.6% of Rev ($656M)
90D Engineering Disclosures0 Published
Investor FAQ IMDX vs MYGN Key Questions & Quantitative Answers
As of Nov 19, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas MYGN carries 45.4/100 (HOLD) at $5.54 (54.0x Forward P/E, -13.3% operating margin). Growth vs. Quality Trade-Off: MYGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. IMDX 45.5/100 HOLD) and 0.63β · 54% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile MYGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MYGN leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while MYGN shifted +10.8%. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.
MYGN screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus MYGN (-40.2% ROE) capital efficiency.
In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.